Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

DOI

From PsychonautWiki Archive
Revision as of 22:45, 1 November 2015 by >PJosepherum (Text replacement - "{{Template:SubstanceBox" to "{{SubstanceBox")
Jump to navigation Jump to search

Template:Proofread

DOI
Chemical Nomenclature
Common names DOI
Substitutive name 2,5-Dimethoxy-4-iodoamphetamine
Systematic name 1-(4-Iodo-2,5-dimethoxyphenyl)-2-propanamine
Class Membership
Psychoactive class Psychedelic
Chemical class Amphetamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



⇣ Oral
Dosage
Threshold 0.5 mg
Light 0.5 - 1 mg
Common 1 - 2 mg
Strong 2 - 3 mg
Heavy 3 mg +
Duration
Total 16 - 24 hours
Onset 1 - 2 hours
Come up 1.5 - 3 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions

DOI or 2,5-Dimethoxy-4-iodoamphetamine is a psychedelic drug and a substituted amphetamine. Unlike other substituted amphetamines, however, it is not a stimulant.[1] It was first synthesized by Alexander Shulgin in the 1991 book PiHKAL: A Chemical Love Story. The drug is used recreationally for its psychedelic and entheogenic effects.

DOI's effects have been compared to LSD, although there are differences that experienced users can distinguish. Besides the longer duration, the trip tends to be more energetic than an LSD trip, with more body load and a different subjective visual experience. The after effects include residual stimulation and difficulty sleeping, which, depending on the dose, may persist for days.[2] It is sometimes sold as a substitute for LSD, or even sold falsely as LSD, which may be dangerous because DOI does not have the same established safety profile as LSD.[3]

DOI is very well researched in comparison to many drugs, despite being relatively uncommon in terms of its recreational usage. This is because it is often used used in research as a radioligand and indicator of the presence of 5-HT2A serotonin receptors.

Chemistry

This chemistry section is incomplete.

You can help by adding to it.

Pharmacology

Main article: Serotonergic psychedelic

DOI's psychedelic effects are believed to come from its efficacy as an agonist at the 5-HT2A, 5-HT2B and 5-HT2C receptors.[4]. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive. DOI and its isomers binding profiles to; specific 5HT receptor sets can be seen in the chart below:

Binding Profile of DOI and its isomers
Receptor Ki (racemic DOI)[5] Ki (R-DOI)[6] Ki (S-DOI)[7] Intrinsic activity[8]
5-HT1A 2355 nM 3843 nM ND ND
5-HT1B 1261 nM ND ND ND
5-HT1D 1241.3 nM ND ND ND
5-HT1E 2970 nM ND ND ND
5-HT1F 2125.44 nM ND ND ND
5-HT2A 0.68 nM 0.65 nM 0.65 nM Partial agonist.
5-HT2B 20.03 nM 53.70318 nM 28.183829 nM Partial agonist/full agonist
5-HT2C 2.38 nM 5.370318 nM 8.317638 nM Full agonist when coupled to phospholipase A. Partial agonist (intrinsic efficacy = 53%), when coupled to phospholipase C.
5-HT5A 1000 nM ND ND ND
5-HT5A 1000 nM ND ND ND
5-HT6 >10000 nM ND ND ND


Outside of triggering psychedelia, DOI has been shown to be an extremely potent inhibitor of tumour necrosis factor-alpha inflammation at picomolar concentrations in cell studies. TNF-alpha is an important target for research into degenerative conditions such as rheumatoid arthritis and Alzheimer's disease, where the disease process involves tissue damage through chronic inflammation. This could make DOI and other 5-HT2A agonists an entirely new area for development of novel treatments for these conditions.[9]

DOI has also been shown to induce rapid growth and reorganization of dendritic spines and synaptic connections with other neurons, processes known to underlie neuroplasticity.[10]

Subjective effects

 This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects

Cognitive effects

Visual effects

Enhancements

Distortions

Geometry

Hallucinatory states

Auditory effects

Multi-sensory effects

Toxicity and harm potential

The toxicity and long-term health effects of recreational DOI use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because DOI is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychedelic community who have tried DOI suggests that there are no negative health effects attributed to simply trying this drug at low to moderate doses or using it very sparingly (but nothing can be completely guaranteed).

Tolerance and addiction potential

DOI is non-habit forming and the desire to use it can actually decrease with use. It is most often self-regulating.

An almost immediate tolerance is built to DOI after ingestion, preventing one from experiencing its full effects more often than every 4-7 days unless they increase their dose significantly.

  • Australia - The Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) of Australia does not list DOI as a prohibited substance.[11]
  • Canada - Listed as a Schedule 1[12] as it is an analogue of amphetamine.[13] The CDSA was updated as a result of the Safe Streets Act changing amphetamines from Schedule 3 to Schedule 1.[14]
  • Denmark - Illegal since 8 April 2007.[15]
  • Sweden - Sveriges riksdag added DOI to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of August 30, 2007, published by Medical Products Agency in their regulation LVFS 2007:10 listed as DOI, 4-jod-2,5-dimetoxi-amfetamin.[16]
  • United States - DOI is not scheduled in the United States, but it is likely that DOI would be considered an analog (of DOB), in which case, sales or possession could be prosecuted under the Federal Analogue Act. DOI is regularly used in animal and in vitro research. Scheduling DOI could cause problems for medical researchers.
  • Florida - DOI is a Schedule I controlled substance in the state of Florida.[17]

See also

References

  1. ↑ DOI TiHKAL | http://www.erowid.org/library/books_online/pihkal/pihkal067.shtml
  2. ↑ DOI TiHKAL | http://www.erowid.org/library/books_online/pihkal/pihkal067.shtml
  3. ↑ LSD BLOTTER ACID MIMICS (ACTUALLY CONTAINING 4-IODO-2,5-DIMETHOXYAMPHETAMINE (DOI) AND 4-CHLORO-2,5-DIMETHOXYAMPHETAMINE (DOC)) IN LANTANA, FLORIDA | http://web.archive.org/web/20090204025435/http://www.usdoj.gov/dea/programs/forensicsci/microgram/mg0608/mg0608.html
  4. ↑ Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model | https://www.ncbi.nlm.nih.gov/pubmed/22517680
  5. ↑ http://pdsp.med.unc.edu/pdsp.php
  6. ↑ http://pdsp.med.unc.edu/pdsp.php
  7. ↑ http://pdsp.med.unc.edu/pdsp.php
  8. ↑ Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model | https://www.ncbi.nlm.nih.gov/pubmed/22517680
  9. ↑ Yu, B; Becnel, J; Zerfaoui, M; Rohatgi, R; Boulares, AH; Nichols, CD (2008). "Serotonin 5-Hydroxytryptamine2A Receptor Activation Suppresses Tumor Necrosis Factor-α-Induced Inflammation with Extraordinary Potency". Journal of Pharmacology and Experimental Therapeutics. 327 (2): 316–323. doi:10.1124/jpet.108.143461. PMID 18708586. 
  10. ↑ "Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling". Journal of Pharmacology and Experimental Therapeutics. Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. 17 November 2009. doi:10.1073/pnas.0905884106. PMID 19889983. 
  11. ↑ Therapeutic Goods Administration. Australian Government Department of Health and Ageing | http://www.comlaw.gov.au/Details/F2013L01607/229bdf2e-7014-4379-b751-0b584f55d699
  12. ↑ http://isomerdesign.com/Cdsa/schedule.php?schedule=1&section=18.5&structure=C
  13. ↑ http://isomerdesign.com/Cdsa/definitions.php?structure=C
  14. ↑ http://www.justice.gc.ca/eng/news-nouv/nr-cp/2012/doc_32759.html
  15. ↑ http://www.erowid.org/chemicals/doc/doc_law.shtml
  16. ↑ http://www.lakemedelsverket.se/upload/lvfs/LVFS_2007-10.pdf
  17. ↑ http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html
Retrieved from "http://psy.st/w/index.php?title=DOI&oldid=47154"